Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cubist Pharmaceuticals and Emisphere Technologies Announce Research Collaboration for Oral Delivery of Daptomycin
Cubist Pharmaceuticals and Emisphere Technologies Announce Research Collaboration for Oral Delivery of Daptomycin CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced a research and development
View HTML
Toggle Summary Data From Emisphere's Oral Insulin Study Presented at the 64th Scientific Sessions of the American Diabetes Association
- Results Suggest Positive Impact on Glycemic Control in Type 2 Diabetics And Desired Activity With No Observed Hypoglycemic Events -
View HTML
Toggle Summary DuPont Pharmaceuticals and Emisphere Announce Agreement for Oral Heparins Development and Marketing
DuPont Pharmaceuticals and Emisphere Announce Agreement for Oral Heparins Development and Marketing WILMINGTON, Del., and TARRYTOWN, N.Y., June 30 /PRNewswire/ -- DuPont Pharmaceuticals Company, a wholly-owned independent subsidiary of DuPont (NYSE: DD) and Emisphere Technologies, Inc.
View HTML
Toggle Summary Emisphere Achieves Second Milestone in Roche Collaboration
Emisphere Achieves Second Milestone in Roche Collaboration TARRYTOWN, N.Y., Feb. 15 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has achieved a second milestone under its November 2004 agreement with Roche to develop new oral formulations of a Roche
View HTML
Toggle Summary Emisphere Amends License Agreement with Novo Nordisk
Emisphere to Receive $7 Million Payment  ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS ) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE: NVO ) for the development and
View HTML
Toggle Summary Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product
Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral
View HTML
Toggle Summary Emisphere and Elan Announce Successful Completion of Additional Clinical Trials for Oral Heparin Preparation; Joint Venture Will Also Develop Oral Low Molecular Weight Heparin Product
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML
Toggle Summary Emisphere and Elan Contribute $10 Million to Heparin Joint Venture
Emisphere and Elan Contribute $10 Million to Heparin Joint Venture Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral
View HTML
Toggle Summary Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements
Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with
View HTML
Toggle Summary Emisphere Announces $13.5 Million Private Placement
Emisphere Announces $13.5 Million Private Placement Hawthorne, NY, May 4, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the closing of a $13.5 million private placement of 5% senior convertible notes. Emisphere plans to use the proceeds of the private placement for general
View HTML

FOLLOW US